XBRANE — Xbrane Biopharma AB Balance Sheet
0.000.00%
Last trade - 00:00
- SEK535.16m
- SEK525.84m
- SEK238.73m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | — | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 164 | 243 | 295 | 194 | 65.4 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5.89 | 58.4 | 50.3 | 47.5 | 34.2 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 248 | 374 | 561 | 514 | 462 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 16.2 | 14.1 | 73.8 | 71 | 88.2 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 339 | 464 | 688 | 691 | 654 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 140 | 189 | 220 | 237 | 327 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 155 | 206 | 257 | 266 | 482 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 184 | 258 | 432 | 425 | 171 |
Total Liabilities & Shareholders' Equity | 339 | 464 | 688 | 691 | 654 |
Total Common Shares Outstanding |